Besides, epigenetic alterations were identified [15C17]

Besides, epigenetic alterations were identified [15C17]. with systemic autoimmune diseases (two with Sj?gren syndrome, 1 with neuropsychiatric lupus, and one with anti-phospholipid autoantibodies). Six patients (67%) benefited from immunotherapy. In addition, eleven cross-sectional studies (six with healthy controls, three with neurological/psychiatric patient controls, and two uncontrolled) were recognized with inconsistent results, but in six studies an association between autoantibodies and OCD was suggested. In summary, the available case reports suggest an association between OCD and autoantibodies in rare cases, which has been supported by initial cross-sectional studies. However, scientific data is still very limited. Thus, further studies on autoantibodies investigated in patients with OCD compared with healthy controls are needed. Subject terms: Diagnostic markers, Molecular neuroscience Introduction Approximately 2% of the population worldwide suffer from obsessive-compulsive disorder (OCD; [1, 2]), frequently first presenting in child years/adolescence or early adulthood [3]. The delayed diagnosis and disease burden results in considerable economic and psychological impairment [4, 5]. Patients with OCD tend to statement poorer quality of life than, for example, patients with depressive disorder or even heroin dependency [6]. Core obsessive-compulsive symptoms (OCS) are ego-dystonic irrational obsessive thoughts that lead to time-consuming repetitive behaviors (compulsions) to reduce stress [7, 8]. Exposure therapy with response prevention as a form of cognitive behavioral therapy (CBT) constitutes the first choice in terms of psychotherapeutic methods for OCD and serotonin reuptake inhibitors (SSRIs) are mainly used for psychopharmacotherapy [9C12]. Nevertheless, treatment resistance rates are high with approximately half of patients not responding sufficiently to first-line therapy [8]. There is increasing evidence that biological components have substantial influence around the development of this disorder. A moderate genetic component with heritability estimates ranging from 27 to 65% has been reported [13, 14]. Besides, epigenetic alterations were recognized [15C17]. Neuroimaging studies point to an aberration of neuronal pathways including cortico-striato-thalamo-cortical circuits [18, 19]. Electroencephalography (EEG) data suggest abnormalities in frontal areas of the brain and overstimulation regarding event-related potentials [20]. Furthermore, neurochemical investigations indicate an imbalance, especially in serotonergic, but also dopaminergic and glutamatergic neurotransmission [7, 8, 18, 21]. An autoimmune hypothesis in some cases was initially postulated based on an association between OCS in children and their exacerbation after infections with beta-hemolytic streptococci [22]. This subgroup of patients has been termed pediatric autoimmune neuropsychiatric disorder associated with streptococcal contamination, or PANDAS. The pathogenic antibodies associated with the IX 207-887 M-protein of beta-hemolytic streptococci are hypothesized to be able to cross the bloodCbrain barrier and cross-react with basal ganglia tissue, which may result in OCS [22C24]. Other studies corroborated this assumption by identifying anti-basal ganglia autoantibodies (ABGA) in children with PANDAS [25C28]. In line with this, Pearlman and colleagues [29] conducted a meta-analysis on ABGA in OCD patients and detected significantly elevated ABGA levels. However, several studies also suggest that other autoantibodies besides ABGA may be associated with OCD and OCS [30C35]. To date, however, systematic analyses on different autoantibodies in OCD are missing. Therefore, the aim of this systematic review is to summarize and analyze the findings on different autoantibodies in patients with Tfpi OCD/OCS. Material and Methods Eligibility criteria Initial research findings comprising case reports, case series, uncontrolled and controlled cross-sectional studies of patients with OCD or OCS reporting on autoantibodies detected in blood/and or cerebrospinal fluid (CSF) were included. Patients of all ages were IX 207-887 analyzed, and no restrictions were placed on the methodology of autoantibody screening. Preliminary results as well as case reports/series and cross-sectional studies reporting findings of patients with OCD and comorbid Tourette syndrome were IX 207-887 excluded. Studies conducted exclusively in animals or with pathogen-associated antibodies (e.g., streptococcal antibodies) were ruled out. Furthermore, all articles that were published in languages.